Sign in
Taking people in Hong KongPhase 2

Tests oral arsenic trioxide with low-intensity treatment for TP53-mutated blood cancers

Tests oral arsenic trioxide in adults with TP53-mutated myeloid blood cancers.

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Oral-ATO for TP53-mutated Myeloid Malignancies
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
7 Feb 2025
Expected to end
Feb 2028
Type of study
Interventional
Treatments tested
  • Oral arsenic trioxide
Record updated
10 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute myeloid leukemia, myelodysplastic neoplasm or chronic myelomonocytic leukemia that carries a TP53 mutation. It includes people not yet treated and people whose disease came back or did not respond.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS) or chronic myelomonocytic leukemia (CMML) by WHO 2022 criteria. Cohort A: not yet treated. Cohort B: relapsed or refractory after 1 or more lines of earlier treatment. Daily-life activity level (ECOG) of 0-2.
Earlier treatment
Cohort A: no earlier treatment. Cohort B: 1 or more earlier lines of treatment that failed. No investigational drug within 14 days (or at least 7 half-lives of that drug, whichever is longer) before the first dose.
Biomarker or test result
A TP53 mutation must be present.

Main reasons for not taking part

  • Known HIV infection, or known active hepatitis B or hepatitis C
  • Uncontrolled, active infection
  • Long QT syndrome, or QTcF of 480 ms or more
  • Kidney function (GFR) below 40 mL/min, or ALT or AST 3 or more times the upper limit of normal
  • Pregnant or breastfeeding, or planning pregnancy during the study

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Willing and able to provide informed consent
  • Age ≥18 years
  • Diagnosis of acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS) or chronic myelonocytic leukaemia (CMML) by World Health Organization (WHO) 2022 criteria (1, 3)
  • Presence of TP53 mutation
  • Previously untreated patients for Cohort A (Treatment-naïve), or Patients failing 1 or more lines of prior treatment for Cohort B (Relapsed and Refractory)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Women of childbearing potential and fertile men must agree to use an approved method of contraception from Screening until 30 days after the last dose of oral arsenic trioxide, ascorbic acid, venetoclax and azacitidine/decitabine/oral-decitabine-cedazuridine
  • Willing and able to provide informed consent
  • Age ≥18 years
  • Diagnosis of acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS) or chronic myelonocytic leukaemia (CMML) by World Health Organization (WHO) 2022 criteria (1, 3)
  • Presence of TP53 mutation
  • Previously untreated patients for Cohort A (Treatment-naïve), or Patients failing 1 or more lines of prior treatment for Cohort B (Relapsed and Refractory)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Women of childbearing potential and fertile men must agree to use an approved method of contraception from Screening until 30 days after the last dose of oral arsenic trioxide, ascorbic acid, venetoclax and azacitidine/decitabine/oral-decitabine-cedazuridine

Who cannot take part

  • Use of an investigational agent within 14 days of study treatment (or at least 7 half-lives of that agent, whichever is longer), prior to the first dose of oral arsenic trioxide
  • Major surgery within 4 weeks of starting the study drug, or not recovered from side effects of surgery
  • Concurrent second active and non-stable malignancy (patients with a concurrent second active but stable malignancy, i.e., non-melanoma skin cancers, are eligible)
  • Known hypersensitivity to arsenic trioxide, ascorbic acid, venetoclax or azacitidine/decitabine/oral-decitabine-cedazuridine or their excipients
  • Uncontrolled, active infection
  • Any other serious medical conditions that could compromise study participation, in the opinion of the investigator
  • Known HIV infection or known, active hepatitis B or hepatitis C infection
  • Known history of long QT syndrome (LQTS) or corrected QT interval by Fridericia formula (QTcF) ≥ 480 ms
  • Evidence at the time of Screening of significant renal or hepatic insufficiency (unless due to hemolysis) as defined by any of the following local laboratory parameters:; Calculated glomerular filtration rate (GFR; using the Cockcroft-Gault equation or eGFR; using CKD-EPI) < 40 mL/min; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 x the local upper limit of normal
  • Pregnant or lactating females, or females planning to become pregnant at any time during the study
  • Unwilling or unable to comply with the study protocol

Where in Hong Kong

  • Queen Mary Hospital - Hong KongHong Kong, Hong KongContact: Harinder Gill, MDTaking people

About the trial

What the trial wants to find out

This is an open-label, phase 2 study of oral arsenic trioxide (Arsenol ®) in combination with ascorbic acid and investigator choice of low-intensity therapy in patients with previously untreated or relapse/refractory TP53-mutated acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS), chronic myelomonocytic leukemia (CMML).

The group in the trial

  • Oral arsenic trixoideTreatment being tested

    Patients will be treated in 28-day cycles. Each cycles will comprise: Oral ATO (10mg/day or 0.15mg/kg/day in patients \< 50kg) from Days 1-14 PLUS: * Oral ascorbic acid (1000mg/day) from Days 1-14 * Azacitidine (75mg/m2/day s.c. or i.v.) from days 1-7; OR Decitabine (20mg/m2/day i.v.) from days 1-5; OR Oral-decitabine-cedazuridine (1 tablet/day) from days 1-5. * Venetoclax (100mg-400mg/day) from Days 1-14 (if used)

    Treatment: Oral arsenic trioxide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2 Study of Oral Arsenic Trioxide (Arsenol ®)-Based Low-intensity Treatment for Previously Untreated or Relapsed/Refractory TP53-mutated Myeloid Malignancies
Plain-language title
Tests oral arsenic trioxide with low-intensity treatment for TP53-mutated blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 June 2025